Literature DB >> 20442371

Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance.

Dayuan Li1, Amit R Patel, Alexander L Klibanov, Christopher M Kramer, Mirta Ruiz, Bum-Yong Kang, Jawahar L Mehta, George A Beller, David K Glover, Craig H Meyer.   

Abstract

BACKGROUND: The oxidized low-density lipoprotein receptor (LDLR) LOX-1 plays a crucial role in atherosclerosis. We sought to detect and assess atherosclerotic plaque in vivo by using single-photon emission computed tomography/computed tomography and magnetic resonance imaging and a molecular probe targeted at LOX-1. METHODS AND
RESULTS: Apolipoprotein E(-/-) mice fed a Western diet and LDLR(-/-) and LDLR(-/-)/LOX-1(-/-) mice fed an atherogenic diet were used. Imaging probes consisted of liposomes decorated with anti-LOX-1 antibodies or nonspecific immunoglobulin G, (111)indium or gadolinium, and 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine fluorescence markers. In vivo imaging was performed 24 hours after intravenous injection (150 microL) of LOX-1 or nonspecific immunoglobulin G probes labeled with either (111)indium (600 muCi) or gadolinium (0.075 mmol/kg), followed by aortic excision for phosphor imaging and Sudan IV staining, or fluorescence imaging and hematoxylin/eosin staining. The LOX-1 probe also colocalized with specific cell types, apoptosis, and matrix metalloproteinase-9 expression in frozen aortic sections. Single-photon emission computed tomography/computed tomography imaging of the LOX-1 probe showed aortic arch "hot spots" in apolipoprotein E(-/-) mice (n=8), confirmed by phosphor imaging. Magnetic resonance imaging showed significant Gd enhancement in atherosclerotic plaques in LDLR(-/-) mice with the LOX-1 (n=7) but not with the nonspecific immunoglobulin G (n=5) probe. No signal enhancement was observed in LDLR(-/-)/LOX-1(-/-) mice injected with the LOX-1 probe (n=5). These results were confirmed by ex vivo fluorescence imaging. The LOX-1 probe bound preferentially to the plaque shoulder, a region with vulnerable plaque features, including extensive LOX-1 expression, macrophage accumulation, apoptosis, and matrix metalloproteinase-9 expression.
CONCLUSIONS: LOX-1 can be used as a target for molecular imaging of atherosclerotic plaque in vivo. Furthermore, the LOX-1 imaging signal is associated with markers of rupture-prone atherosclerotic plaque.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20442371      PMCID: PMC2955298          DOI: 10.1161/CIRCIMAGING.109.896654

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  38 in total

Review 1.  Dual-modality probes for in vivo molecular imaging.

Authors:  Seulki Lee; Xiaoyuan Chen
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

2.  Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species.

Authors:  L Cominacini; A F Pasini; U Garbin; A Davoli; M L Tosetti; M Campagnola; A Rigoni; A M Pastorino; V Lo Cascio; T Sawamura
Journal:  J Biol Chem       Date:  2000-04-28       Impact factor: 5.157

3.  A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1.

Authors:  M Kakutani; T Masaki; T Sawamura
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 4.  Apoptosis in atherosclerosis. Does it contribute to plaque instability?

Authors:  F D Kolodgie; J Narula; N Haider; R Virmani
Journal:  Cardiol Clin       Date:  2001-02       Impact factor: 2.213

5.  Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells.

Authors:  D Li; J L Mehta
Journal:  Circulation       Date:  2000-06-27       Impact factor: 29.690

6.  Oxidized low-density lipoprotein receptor LOX-1 and apoptosis in human atherosclerotic lesions.

Authors:  D Y Li; H J Chen; E D Staples; K Ozaki; B Annex; B K Singh; R Vermani; J L Mehta
Journal:  J Cardiovasc Pharmacol Ther       Date:  2002-07       Impact factor: 2.457

Review 7.  Apoptotic cell death in atherosclerosis.

Authors:  Trevor D Littlewood; Martin R Bennett
Journal:  Curr Opin Lipidol       Date:  2003-10       Impact factor: 4.776

8.  Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation.

Authors:  Yves Delneste; Giovanni Magistrelli; Jean Gauchat; Jean Haeuw; Jean Aubry; Kayo Nakamura; Naoko Kawakami-Honda; Liliane Goetsch; Tatsuya Sawamura; Jean Bonnefoy; Pascale Jeannin
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

9.  LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells.

Authors:  Dayuan Li; Ling Liu; Hongjiang Chen; Tatsuya Sawamura; Subramanian Ranganathan; Jawahar L Mehta
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

10.  LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells.

Authors:  Dayuan Li; Ling Liu; Hongjiang Chen; Tatsuya Sawamura; Jawahar L Mehta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-13       Impact factor: 8.311

View more
  47 in total

1.  LOX-1 abrogation reduces cardiac hypertrophy and collagen accumulation following chronic ischemia in the mouse.

Authors:  J Lu; X Wang; W Wang; H Muniyappa; C Hu; S Mitra; B Long; K Das; J L Mehta
Journal:  Gene Ther       Date:  2011-09-22       Impact factor: 5.250

2.  PET, CT and MRI characterisation of the atherosclerotic plaque.

Authors:  Giovanni Lucignani; Michael Schäfers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12       Impact factor: 9.236

Review 3.  Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.

Authors:  Thibaut Quillard; Peter Libby
Journal:  Circ Res       Date:  2012-07-06       Impact factor: 17.367

4.  Specific targeting of atherosclerotic plaques in ApoE(-/-) mice using a new Camelid sdAb binding the vulnerable plaque marker LOX-1.

Authors:  Jens De Vos; Iris Mathijs; Catarina Xavier; Sam Massa; Ulrich Wernery; Luc Bouwens; Tony Lahoutte; Serge Muyldermans; Nick Devoogdt
Journal:  Mol Imaging Biol       Date:  2014-10       Impact factor: 3.488

5.  LOX-1-Targeted Iron Oxide Nanoparticles Detect Early Diabetic Nephropathy in db/db Mice.

Authors:  Bing Luo; Song Wen; Yu-Chen Chen; Ying Cui; Fa-Bao Gao; Yu-Yu Yao; Sheng-Hong Ju; Gao-Jun Teng
Journal:  Mol Imaging Biol       Date:  2015-10       Impact factor: 3.488

6.  Biodistribution and Radiation Dosimetry of 124I-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.

Authors:  Catherine A Foss; Donika Plyku; Alvaro A Ordonez; Julian Sanchez-Bautista; Hailey B Rosenthal; Il Minn; Martin A Lodge; Martin G Pomper; George Sgouros; Sanjay K Jain
Journal:  J Nucl Med       Date:  2018-04-26       Impact factor: 10.057

Review 7.  Imaging Macrophage-associated Inflammation.

Authors:  Catherine A Foss; Julian Sanchez-Bautista; Sanjay K Jain
Journal:  Semin Nucl Med       Date:  2018-02-13       Impact factor: 4.446

8.  Efficacy and Safety of Loading-Dose Rosuvastatin Therapy in Elderly Patients with Acute Coronary Syndromes Undergoing Elective Percutaneous Coronary Intervention.

Authors:  Yungen Jiao; Feng Hu; Zhengang Zhang; Kaizheng Gong; Xiaoning Sun; Aihua Li; Naifeng Liu
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

Review 9.  Molecular imaging in cardiovascular disease: Which methods, which diseases?

Authors:  Jonathan R Lindner; Albert Sinusas
Journal:  J Nucl Cardiol       Date:  2013-12       Impact factor: 5.952

10.  Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis.

Authors:  Claudia Calcagno; Sarayu Ramachandran; Antoine Millon; Philip M Robson; Venkatesh Mani; Zahi Fayad
Journal:  Curr Cardiovasc Imaging Rep       Date:  2012-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.